蛋白酪氨酸磷酸酶PTP-PEP与14-3-3τ蛋白互作调控T细胞活化的机制研究
批准号:
32100992
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
于阳
依托单位:
学科分类:
分子生物物理
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
于阳
中文摘要
蛋白酪氨酸磷酸酶PTP-PEP是T细胞活化的负调节因子,其功能异常能引起多种自体免疫性疾病。但PTP-PEP对T细胞活化的调节机制尚未得到更深入的研究。本项目发现PTP-PEP可调控TCR表达,并采用酵母双杂交系统发现了PTP-PEP新的互作蛋白—14-3-3τ,明确了PTP-PEP P2结构域对二者互作至关重要。PTP-PEP可调控14-3-3τ的酪氨酸磷酸化。在T细胞中,14-3-3τ可与PTP-PEP底物c-Cbl结合,而c-Cbl为TCR降解过程的重要调控因子。据此推测,14-3-3τ作为桥梁协助PTP-PEP与c-cbl接触,并精准调控c-Cbl酪氨酸磷酸化与TCR的表达,影响活化信号传递,避免T细胞过度激活而诱发自体免疫性疾病。本项目拟解析PTP-PEP与14-3-3τ互作对TCR表达、T细胞信号传导及细胞因子分泌等功能的影响,从新角度阐明PTP-PEP调控T细胞活化的机制。
英文摘要
PTP-PEP is a member of proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatase (PTP), known as proline-enriched phosphatase (PEP). The C-terminal of PTP-PEP contains four proline-rich motif domains, P1, P2, P3 and P4, which are associated with protein interaction. P1 motif binds to Src homology 3 (SH3) domain of protein tyrosine kinase Csk to form complex and suppresses phosphorylation of Csk. Originally, the researchers expressed a substrate-trapping mutant PTP-PEP C227S, in pervanadate-treated T cells and led to the identification of Lck, Fyn (Src homology family protein tyrosine kinases, PTKs), TCR-CD3ζ, and Zap-70 (ζ-associated protein kinase 70) as primary substrates of PTP-PEP, which played the important roles in TCR signaling pathway. Tons of experiments demonstrated that PTP-PEP inhibited TCR signaling by dephosphorylation of the TCR signaling downstream regulators, to avoid the excessive activation of the immune system and protect the body. In recent years, most studies have focused on that a single nucleotide polymorphism (SNP) of PTP-PEP/PTPN22 gene can lead to various Autoimmune Diseases. However, there was no in-depth analysis about PTP-PEP on its potential regulatory mechanism of T cell activation. In the initial stage of our study, we found that the expression of T cell receptor (TCR) increased significantly. Furthermore, we identified a new partner of PTP-PEP, which was the 14-3-3τ protein by using the yeast two-hybrid system. We discovered that PTP-PEP interacted with 14-3-3τ via P2 motif. In addition, PTP-PEP dephosphorylated 14-3-3τ. 14-3-3τ plays a crucial role in the regulation of T cell activation and signal transduction, suggesting that PTP-PEP may regulate T cell activation via the interaction with 14-3-3τ. In T cells, the 14-3-3τ bind to c -Cbl that is the substrates of PTP-PEP and is an important regulators of TCR degradation processes. Therefore, it is speculated that 14-3-3τ as a bridge to assist PTP-PEP contact with c-Cbl, accurately regulate the tyrosine phosphorylation and TCR expression, thereby affecting activation signaling and avoiding excessive activation of T cells to induce autoimmune diseases. In this study, we plan to investigate the regulation mechanism of T cell receptor expression, T cell signaling and cytokine secretion by their interaction. Overall, we aim to illuminate the biological function of PTP-PEP on regulating T cell activation, and provide some effective and safe options to treat autoimmune disease from the current study.
蛋白酪氨酸磷酸酶PTP-PEP/PTPN22负调控TCR介导的信号通路关键蛋白的酪氨酸磷酸化而抑制T细胞的活化,成为机体免于自身免疫性疾病伤害的重要保障,对于维持T细胞的稳定状态,防止T细胞过度活化具有重要的意义。然而,针对PTP-PEP参与免疫系统各项功能的研究局限在其调控TCR信号通路分子的酪氨酸磷酸化方面,并未阐明其更深层次的分子机理。.本项目首先筛选出新的PTP-PEP互作蛋白14-3-3。PTP-PEP依赖Ser640位点与14-3-3特异性结合,并调控14-3-3 Tyr179位点的磷酸化水平,从而影响14-3-3与Shc之间的结合及14-3-3对PI3K的抑制作用,进而调控PI3K/Akt/mTOR信号通路的活化,最终影响IL-1、IL2、IFNγ以及TNF等细胞因子的表达,参与T细胞的免疫应答。此外,本项目首次成功构建了失去磷酸酶活性的PTP-PEP CS转基因小鼠模型,并发现PTP-PEP失去酪氨酸磷酸酶活性可抑制TCR的内在化并促进其再循环作用,增加细胞表面TCR-CD3复合体的表达,从而促进阳性选择和阴性选择,影响胸腺及外周免疫器官细胞的发育,开发出PTP-PEP在调节TCR表达和T细胞发育中的新功能。本项目还首次尝试解析了PTP-PEP保护急性溃疡性结肠炎发病的机制,PTP-PEP通过靶向JAK/STAT通路,维持Th1/Th17平衡,从而维持肠道稳态。而PTP-PEP CS失活导致STAT3活化减少而STAT1活化增多,进而使Th17分化减少,致病性Th1细胞过度活化,最终致使炎症加重。本项目还探索了蛋白酪氨酸磷酸酶PTPN18抑制乳腺癌转移的分子机制,研究发现:PTPN18由MVP和importin β2协同介导入核,核内PTPN18调控ETS1的酪氨酸磷酸化进而促进了ETS1的降解作用。ETS1蛋白降解后无法有效启动下游基因转录,导致乳腺癌的EMT、侵袭和迁移等过程受到影响。上述发现强调了PTPN18作为早期治疗干预乳腺癌进展的潜在靶点的作用。.本项目全面解析了PTP-PEP参与调控TCR表达、T细胞发育、T细胞活化、T细胞分化及免疫应答等过程的分子机制。进一步证明PTP-PEP在免疫系统稳态中至关重要的作用,为免疫系统的构建提供了理论基础,更为溃疡性结肠炎的治疗选择提供新的理论依据及方向。
国内基金
海外基金